Tandem Diabetes Care (TNDM Quick QuoteTNDM - Free Report) is pushing two levers at once in 2026: improving operating performance while shifting more U.S. business toward a pharmacy-based, pay-as-you-go pathway. That mix can make near-term comparisons noisy.

First-quarter results helped clarify what matters most. The company is showing progress on shipments, profitability and cash flow while keeping its full-year framework intact. 

TNDM’s Q1 2026 Beat Shows Improving Execution

First-quarter worldwide revenue rose 5.5% year over year to $247.2 million, while the company shipped more than 19,000 pumps in the United States and more than 10,000 internationally. 

The quality of that growth improved. Gross margin expanded 482 basis points to 55.3%, supported by a 4.8% decline in cost of sales. Operating cash flow turned positive at $11.1 million versus a $21.2 million outflow a year ago.

For an automated insulin delivery company, these metrics are linked. Higher pump shipments expand the installed base. That base is what drives recurring supply revenue over time, so margin improvement and cash generation help fund growth without sacrificing flexibility. 

In the first quarter, TNDM shares have plunged 10.9% compared with the industry’s 15.3% decline. 

Image Source: Zacks Investment Research

Tandem’s Pay-As-You-Go Shift Changes Revenue Timing

Tandem has launched a pay-as-you-go reimbursement model in the U.S. pharmacy channel, building on expanded pharmacy benefit coverage and earlier progress moving t:slim supplies into pharmacy. 

The trade-off is timing. Moving more starts into a pharmacy pathway can reduce near-term sales because reimbursement and revenue recognition patterns differ from a traditional durable medical equipment approach. The payoff is a lower upfront barrier for new pump starts, which can widen the funnel, especially for patients converting from multiple daily injections. 

Early traction is visible but still modest. Pharmacy sales represented 6% of U.S. sales in the first quarter, leaving meaningful runway for mix shift. “End-to-end execution” here means winning payer access, educating prescribers and patients, onboarding smoothly and delivering a customer experience that supports retention. 

TNDM’s Product Stack: Mobi, t:slim X2, Control-IQ

Tandem’s pump portfolio centers on Tandem Mobi and t:slim X2, both powered by Control-IQ advanced hybrid closed-loop technology. Control-IQ, launched in January 2020, is designed to help increase time in the targeted glycemic range, which is a key clinical outcome in insulin therapy. 

The product strategy is also about continuity. The flagship t:slim X2 is described as the smallest durable insulin pump available and is the only available pump capable of remote feature updates. That matters because remote updates help keep users current without requiring a full hardware replacement cycle. 

In a competitive market that includes players like Insulet Corporation (PODD Quick QuotePODD - Free Report) , platform continuity can create “switching friction.” Keeping customers inside a familiar ecosystem supports retention while giving the company a cleaner path to attach more recurring supplies over time. 

Tandem’s Sensor and Smartphone Links Reduce Switching

Compatibility is another pillar of that ecosystem. As part of its automated insulin delivery systems, Tandem supports pump integration with multiple continuous glucose monitoring sensors to create customizable options for people living with diabetes. 

The company began offering the t:slim X2 integrated with the Dexcom G7 sensor in December 2023 (and outside the United States in January 2024). DexCom, Inc. (DXCM Quick QuoteDXCM - Free Report) is also listed among industry peers, underscoring how central sensor partnerships are to automated insulin delivery performance and patient choice. 

Smartphone flexibility is moving the same direction. In the first quarter, Tandem expanded the Mobi ecosystem by adding Android compatibility, broadening access for patients who prefer that platform. Over 2026, management expects additional milestones that expand sensor compatibility across pumps and continue building out the connected-care ecosystem. 

The Zacks Consensus Estimate for TNDM’s 2026 sales and loss per share implies a year-over-year improvement of 5.9% and 73.3%, respectively. The bottom-line estimates have moved north in the past 60 days.

Image Source: Zacks Investment Research

Tandem Risks: Supply Limits, Pricing, and GLP-1 Pressure

Execution risks remain. Tandem has cited ongoing infusion set supply shortages, and management’s customer experience and gross margin initiatives depend partly on successful launches such as extended-wear sets. Delays in product filings, integration timelines, or quality events that trigger recalls could reduce starts and raise costs. 

Competition is another pressure point. Larger rivals can use discounts, rebates and broader distribution to influence payer access, limiting Tandem’s flexibility to raise prices, particularly as pharmacy coverage expands. Management also noted that GLP-1 adoption has likely had a negative impact on the insulin therapy market since 2023. 

For next quarter, investors should watch three signals: whether pump shipment strength persists, whether pharmacy mix moves higher without destabilizing near-term revenue trends, and whether gross margin and operating cash flow continue to improve. With Tandem carrying a Zacks Rank #2 (Buy), those checkpoints can help validate whether the 2026 reset is translating into durable fundamentals. 

You can see the complete list of today’s Zacks Rank #1 (Strong Buy) stocks here.